CSF2 and rheumatoid arthritis: Anti-GM-CSF (mavrilimumab) therapy has had success in RA clinical trials (294), and anti-G-CSF therapy is effective in treating murine arthritis, both inhibiting neutrophil migration into joints, and suppressing cytokine production (304).